Abstract
Granzyme B (gzmB) of cytotoxic T lymphocytes (CTL) is essential for recovery from intracellular pathogens, but the molecular basis of its action is still unresolved. Here, we analyzed gzmB-mediated death pathways under physiological conditions using ex vivo virus-immune CTLs that express perf and gzmB, but not gzmA (gzmB+CTL). We show that gzmB+CTL abrogate target cell proliferation most likely by inducing cell death, independent of caspases and mitochondrial signaling. In addition, the data reveal that gzmB+CTL independently induce pro-apoptotic processes either via caspase-3/-7, leading to plasma membrane perturbance and ROS production or via Bid/Bak/Bax, resulting in cytochrome c release and that both pathways elicit loss of ΔΨm. Our data provide evidence for a pleiotropic pro-apoptotic function of gzmB presumably to counteract evasion strategies of pathogens and to control tumors.
Similar content being viewed by others
Main
Induction of programmed cell death (apoptosis) is a critical process in the host defense against intracellular pathogens and tumors. Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) are the main players in these processes.1 NK/CTL-induced apoptosis of infected or transformed target cells is mediated by the cytoplasmic granule components perforin (perf) and two abundant serine proteinases with highly distinct and restricted proteolytic activities, i.e. granzyme (gzm) A and gzmB.2, 3 Previous studies have shown that gzmA and gzmB, when administered intracellularly together with perf, are able to induce, independently, various pro-apoptotic processes associated with target cell death.4, 5 By employing purified gzmA/gzmB or CTL from mice deficient in gzmA and/or gzmB, it was demonstrated that mitochondrial damage is a key step in gzmA- and gzmB-induced apoptosis4, 5, 6 but that caspase activation only occurs in the presence of gzmB.4, 6, 7
Once released into the cytoplasm, gzmB was proposed to act via two mechanisms to trigger pro-apoptotic events: (1) to activate the effector caspase-3 by proteolytic processing8 and (2) to bypass caspase-3 activation and directly cleave cellular substrates implicated in the execution and/or morphology of apoptosis.12 For the first mechanism, gzmB-activated caspase-3 cleaves dozens of cellular substrates, including the inhibitor ICAD which, upon degradation, releases the active endonuclease CAD for intranucleosomal degradation. In addition, active caspase-3 was shown to indirectly induce reactive oxygen species (ROS) production by targeting the p75 subunit of respiratory chain complexes I and II in previously permeabilized mitochondria.9 Through the action of cytosolic NADPH oxidase, active caspase-3 can also induce hydrogen peroxide and ROS production independent of mitochondria.10 Finally, caspase-3 activation by gzmB seems to be a key factor for the exposure of phosphatidylserine (PS) on the cell surface, one of several ‘eat-me’ signals for effective phagocytosis of apoptotic vesicles11 as well as for the cellular uptake of propidium iodide (PI) due to increased plasma membrane permeability.6, 8, 12 Other caspases such as caspase-2, -6, -7, -8, -9 and -10 have been reported to serve as direct or indirect targets of gzmB, but may amplify/enhance rather than trigger CTL-mediated apoptosis.13
For the second mechanism, gzmB was found to directly cleave a number of structural and regulatory proteins of the cytoskeleton, cytosol and nucleus.4, 5, 8, 14, 15, 16, 17 This constitutes a caspase-independent gzmB trigger of CTL-mediated cell death, but the contribution of each substrate cleavage event to cell death remains poorly defined. A notable exception is the BH3-only protein Bid. This protein, belonging to the Bcl-2 family of apoptosis regulators, can either be processed to truncated Bid (tBid) by caspase-8 in the death-receptor signaling pathway18 or, at an alternative cleavage site, by gzmB during CTL-mediated cell death.8, 17 tBid is known to translocate to mitochondria where it activates Bax and/or Bak, two pro-apoptotic members of the Bcl-2 family that mediate increased mitochondrial membrane permeability and the release of apoptogenic factors, such as cytochrome c, apoptosis-inducing factor (AIF) and endonuclease G (endoG) from the intermembrane space into the cytosol.19 While the latter two factors trigger caspase-independent death signaling pathways, cytochrome c binds to Apaf-1 and recruits caspase-9 into a high molecular weight heptameric structure called the apoptosome, which is then responsible for activating effector caspase-3 and -7. In contrast to the direct processing and activation of caspase-3, this tBid/Bax/Bak-mediated mitochondrial pathway would be an indirect mode of action of gzmB to activate caspase-3 and -7.
At present, there is some controversy regarding the interplay of these two modes of actions of gzmB as well as the exact order of the events triggered by this protease during CTL-mediated apoptosis. The main focus of research has been directed toward mechanisms of how gzmB initiates mitochondrial damage. One pathway is thought to involve the direct action of gzmB on mitochondria to provoke suppression of mitochondrial transmembrane potential (ΔΨm) and increased ROS production without the release of apoptogenic factors such as cytochrome c.20 Another pathway was shown to require gzmB-mediated Bid cleavage to release cytochrome c as well as to trigger ΔΨm loss and/or ROS production.17 Moreover, for the concomitant induction of AIF and endoG release from mitochondria by gzmB and a sustained ΔΨm loss, additional activation of caspases seems to be required.12 Finally, others have suggested that neither Bid nor Bak and Bax are necessary for initiating mitochondrial perturbation,7, 21 but that caspases21 or other cytosolic factors7 are needed. Recent evidence from caspase-3/-7 double knockout cells has lent support to the notion that effector caspases can be critical mediators of mitochondrial events during apoptosis,22 but it has remained enigmatic to what extent they play a role in gzmB-initiated mitochondrial signaling leading to cell death.17, 21
The major hurdle for dissecting the molecular actions of gzmB during CTL-mediated cell death has been the use of artificial in vitro or semi-intact cellular systems with purified gzmB, gzmA and perf preparations rather than cell-based CTL assays. Here, we have used physiological conditions namely ex vivo virus-immune CTLs that express perf and gzmB, but not gzmA (gzmB+CTL) or any other functionally active gzm to reevaluate the pro-apoptotic potential of gzmB under more physiological conditions.
Results
Experimental system
CTLs were ex vivo-derived virus-immune CD8+ T cells from gzmA−/− mice 8 days after lymphocytic choriomeningitis virus (LCMV) infection. These cells express perf and gzmB but not gzmA (gzmB+CTL; Supplementary Figure S1). As target cells we used mouse embryonic fibroblasts (MEFs) derived from wild-type (MEF.wt) and knockout (ko) mutant mice with deficiencies of either, Bid (MEF.Bid−/−), Bak × Bax (MEF.Bak × Bax−/−), caspase-3 (MEF.Casp 3−/−), caspase-7 (MEF.Casp 7−/−) or both (MEF.Casp 3 × 7−/−) or of caspase-9 (MEF.Casp 9−/−).
As previously reported,6 gzmB+CTL contained similar percentages of gp33/Db pentamer+ T cells to those from B6 (C57BL/6), gzmA × B−/− and perf−/− mice (8 versus 7, 10 and 11%, respectively; Supplementary Figure S1a). The levels of gzmB were also roughly the same in gzmB+CTL, B6 CTL and perf−/−CTL and not detectable in gzmA × B−/−CTL (Supplementary Figure S1b). All four ex vivo CTL populations, independent of their genotype, expressed gzmK transcripts, but lacked mRNA for gzmC, D, E, F, G and M, with the exception of perf−/−CTL, which expressed low levels of gzmC transcripts (Supplementary Figure S1d).
gzmB+CTLs have a similar potential as B6 CTL to induce cell death (Pardo et al.6and data not shown), loss of plasma membrane integrity (monitored by exposure of PS at the plasma membrane and incorporation of PI) and severe mitochondrial perturbation (monitored by reduction of the ΔΨm and increase in the generation of ROS) when tested on gp33-pulsed MEF.wt cells (Supplementary Figure S2a, b). These data indicate that CTL/target cell interaction and subsequent exocytosis is normal in gzmB+CTL. They also confirm previous results with EL4 target cells6 showing that CTL-induced loss of plasma membrane and mitochondrial integrity as well as cell death is readily elicited by gzmB in the absence of gzmA. In contrast to gzmB+CTL, both gzmA × B−/− and perf−/−CTL showed only marginal, if any, pro-apoptotic manifestations (Supplementary Figure S3a, b), and were unable to kill MEF.wt cells, as determined by a cell survival assay (Supplementary Figure S3c; and Pardo et al.6). However, all three CTL populations were similarly able to mobilize Lamp-1 to the cell surface after incubation with gp33-labeled MEF.wt cells (Supplementary Figure S3d). These data exclude any contribution from additional proteases, including gzmK (transcripts expressed in all wt and gzmA/B ko strains; see above), to the pro-apoptotic activities of gzmB+CTL and suggest that the intracellular processes induced by gzmB+CTL in MEF.wt cells, including cell death, are exclusively due to gzmB.
As different MEF targets were used, we determined whether all mutant MEFs had the same ability as MEF.wt cells to induce degranulation of gzmB+CTL upon antigen recognition. For this purpose, degranulation of gzmB+CTL was determined by monitoring expression of the lysosomal marker Lamp-1 on their plasma membrane, following incubation with MEF.wt cells in the presence or absence of gp33. As shown in Supplementary Figure S1c, similar expression levels of Lamp-1 were seen in gzmB+CTL after incubation with any of the gp33-pulsed, but not mock-treated MEF lines.
Bid and Bak/Bax are critical for gzmB+CTL-induced cytochrome c release, but not for plasma membrane perturbation, mitochondrial depolarization or target cell killing
We first tested which of the pro-apoptotic effects induced by gzmB+CTL are governed through the Bid/Bak/Bax-mediated mitochondrial axis in our experimental system. As shown in Figure 1, PS exposure and PI incorporation (Figure 1a and c), as well as reduction of ΔΨm and generation of ROS (Figure 1b and d), were elicited to the same extent by gzmB+CTL in MEF.wt and both koMEF lines, when assayed at 4 h of incubation. However, when tested at an earlier time point (i.e. after 1.) a delay in ΔΨm loss and generation of ROS (Figure 1f), but not of PS exposure and PI incorporation (Figure 1e) were observed in MEF.Bid−/− and MEF.Bak × Bax−/− compared to MEF.wt cells. In relation to MEF.wt cells, up to 90% of MEF.Bid−/− and MEF.Bak × Bax−/− cells died upon incubation with gzmB+CTLs for 4 h at an effector:target (E:T) ratio of 10:1 (Figure 2a). In addition, both MEF.wt and MEF.Bak × Bax−/− cells were similarly susceptible to gzmB+CTL-induced cell death, when tested at different E:T (10:1, 3:1 and 1:1). In contrast, while the release of cytochrome c was readily detected in MEF.wt, it was almost completely absent in MEF.Bid−/− or MEF.Bak × Bak−/− cells (Figure 3a). This process was independent of caspase-3, -7 and -9 as the gzmB+CTL-mediated release of cytochrome c was reduced neither in MEF.wt cells pretreated with the pan-caspase inhibitor Ac-ZVAD-fmk (Supplementary Figure S4a) nor in MEF.Casp 3 × 7−/− or in MEF.Casp 9−/− cells (Figure 3b). These data indicate that Bid and Bak/Bax are critical for gzmB-induced cytochrome c release, but not for ROS production, suppression of ΔΨm, perturbation of the plasma membrane and, most surprisingly, cell death. Our finding supports some previous work where purified gzmB was used to measure plasma and mitochondrial membrane perturbation,7, 21 but apparently contradicts those data obtained with Bid-deficient cells where resistance to gzmB-mediated cell death was shown.23 The role of Bid and Bax/Bak in gzmB-mediated cytochrome c release was further bolstered by the fact that Bid was effectively cleaved in MEF.wt cells after incubation with gzmB+CTL but not gzmB−/−CTL (Figure 3d). Moreover, Bax and Bak activation, as determined by the detection of their active state with N-terminal antibodies, was only observed when gzmB+CTLs were incubated with MEF.wt, but not with MEF.Bid−/− cells (Figure 3c).
Caspase-3 and -7 are activated by gzmB+CTL, independently of Bid, Bax and Bak but neither of the two enzymes are required for gzmB+CTL-mediated target cell death
Next, we determined whether effector caspase-3 and -7 were activated and/or required for gzmB+CTL-mediated cell death of gp33-pulsed MEFs. For that purpose, gzmB+CTLs were incubated with MEF.wt cells previously treated with either the general caspase inhibitor Ac-ZVAD-fmk, the more caspase-3/-7 selective inhibitor Ac-DEVD-fmk or with MEF.Casp 3 × 7−/− cells; untreated MEF.wt cells served as a control.
Similar to previous findings with EL4 thymoma cells as targets,6 the treatment of MEF.wt cells with Ac-ZVAD-fmk did not prevent target cell death by gzmB+CTL (Figure 2a). This was also the case when MEF.Bid−/− and MEF.Bak × Bax−/− cells were used as targets under similar conditions (Figure 2a). Furthermore, gzmB+CTL-mediated target cell death proceeded with similar efficiency in MEF.wt, MEF.Casp 9−/− and MEF.Casp 3 × 7−/− (Figure 2b), as well as in MEF.wt and MEF.Bak × Bax−/−, previously loaded with Ac-ZVAD-fmk, even when lower E:T (3:1 and 1:1) ratios were used (Figure 2c). These data suggest that gzmB-induced target cell death occurs primarily through a caspase-independent mechanism.
To determine if caspase-3 was nevertheless activated in the gp33-pulsed MEF.wt cells upon gzmB+CTL co-incubation, we measured caspase-3 activation by FACS analysis using an antibody against the active form of caspase-3 (mAb C92-605). Figure 4a shows that about 25 and 50% of the MEF.wt cells exhibited increased caspase-3 activation upon gzmB+CTL challenge in the presence of the gp33 peptide for 1 and 4 h, respectively. Comparable numbers of cells expressing active caspase-3 were found in gzmB+CTL-treated MEF.Bid−/− (41%, 1 h; 72%, 4 h) and MEF.Bax/Bak−/− (35%, 1 h; 61%, 4 h) (Figure 4a), indicating that gzmB most likely cleaved and activated caspase-3 directly, bypassing the need of mitochondrial events such as Bid-induced Bax/Bak activation and cytochrome c release.
gzmB+CTL-induced activation of caspase-3 and -7 is needed for PS surface exposure and plasma membrane permeability
The question remained for what purpose, if not cell death, caspase-3 was activated in the gp33-pulsed target cells in response to gzmB+CTL incubation. We therefore first tested the contribution of caspases in general and caspase-3 and -7 in particular in gzmB+CTL-induced PS exposure and plasma membrane permeability. Figure 4b shows that when Ac-ZVAD-fmk was added to gp33-pulsed MEF.wt cells incubated with gzmB+CTL, the percentages of annexin-V+ and PI+ target cells were drastically reduced as compared to untreated cells as shown previously.6 A similar result was obtained with gzmB+CTL-treated MEF.Casp 3 × 7−/− cells, while MEF.wt cells showed a marked increase in PS exposure and PI permeability (Figure 5a). Using MEF.Casp 3−/− and MEF.Casp 7−/− cells to analyze the individual roles of caspase-3 and -7 in this process, we noted a synergistic effect of caspase-3 and -7 (Figure 5c); remarkably, caspase-7 was able to replace caspase-3 in inducing membrane damage. In contrast, caspase-9, a caspase-3-activating initiator caspase of the mitochondrial pathway, did not play any role in these effects as MEF.Casp 9−/− cells were indistinguishable from MEF.wt cells in gzmB-induced annexin-V expression and PI incorporation (Figure 5a). These data extend previous findings by us and others showing that caspase-3 activation results in surface exposure of PS and increased plasma membrane permeability.6, 8, 12 However, these results suggest that gzmB+CTL-induced PS exposure on target cells does not depend on mitochondrial signaling (Bax/Bak activation, cytochrome c release, caspase-9 activation), at least at early stages of CTL-target cell interaction (4 h), and are not required for final gzmB+CTL-induced target cell killing (see above, Figure 2a and b).
gzmB+CTL-induced activation of caspase-3 and -7 but not caspase-9 is needed for ROS production, but not for the loss of the mitochondrial membrane potential
We next tested the role of caspase-3, -7 and -9 in gzmB+CTL-induced ΔΨm loss and the generation of ROS in MEF.wt, MEF.Casp 3 × 7−/− and MEF.Casp 9−/− cells (Figure 5b). We found that gzmB+CTL induced comparable levels of ΔΨm loss in MEF.wt, MEF.Casp 3 × 7−/− and MEF.Casp 9−/− cells (Figure 5b). This indicates that gzmB-induced reduction of ΔΨm is independent of direct or indirect – via caspase-9 and apoptosome formation – activation of effector caspases. In contrast, ROS generation was significantly reduced in MEF.Casp 3 × 7−/− as compared to MEF.wt cells (Figure 5b). Both caspases seem to be needed for optimal induction of ROS, as MEF.Casp 3−/− and MEF.Casp 7−/− cells showed similar impairment in ROS production as MEF.Casp 3 × 7−/− cells (Figure 5b and c). These data imply that gzmB-induced ROS generation critically depends on the activation of effector caspases, in particular caspase-3 and -7. However, as for PS exposure and PI uptake, ROS production was probably the result of a direct activation of caspase-3 and -7 by gzmB (bypassing mitochondria) because MEF.Casp 9−/− (Figure 5b) as well as MEF.Bid−/− and MEF.Bax/Bak−/− MEF (Figure 1b and d) cells exhibited similar ROS production in response to gzmB+CTL as MEF.wt cells.
gzmB+CTL-induced loss of the mitochondrial membrane potential is triggered via two independent pathways
In Figures 1 and 5, we show that MEF.Bid−/− and MEF.Bak × Bax−/− as well as MEF.Casp 3 × 7−/− exhibit a similar loss of ΔΨm as seen in MEF.wt cells, indicating that this pro-apoptotic response was neither individually dependent on Bid/Bax/Bak nor on caspase-3/-7. However, it is possible that once Bid or Bax/Bak are deleted, the loss of ΔΨm is mediated via caspases. As shown in Figure 6, this was indeed the case. When gzmB+CTLs were incubated with gp33-pulsed MEF.Bid−/− and MEF.Bak × Bax−/− in the presence of the general caspase inhibitor Ac-ZVAD-fmk or the caspase-3/-7 inhibitor Ac-DEVD-fmk, the induction of ΔΨm loss was severely diminished (Figure 6). Together with the finding that the levels of ΔΨm loss and ROS production were diminished in MEF.Bid−/− and MEF.Bak × Bax−/− compared to MEF.wt, when incubated with gzmB+CTL for 1 h, but not 4 h (Figure 1f), the data indicate that gzmB is able to induce two independent pathways of mitochondrial depolarization: one mediated by Bid-dependent Bak/Bax activation in the absence of caspase (Figure 5b) and the other by activation of both caspase-3 and -7, and independent of Bid/Bak/Bax (Figure 1b and d). Only when both pathways are simultaneously inhibited, then the integrity of mitochondria from gzmB-challenged target cells is maintained. However, gzmB+CTL-mediated cell death still occurs under the latter conditions, as revealed by a cell survival assay (Figure 2a).
Discussion
The multitude of independent and/or interconnecting pro-apoptotic pathways, which have been described so far renders it difficult to define a general model of gzmB-induced cell death. This may in part be due to the fact that gzmB proteins, CTLs and target cells from different species have been used interchangeably, but they in fact exhibit distinct qualities.24, 25, 26 In addition, the substrate specificity of gzmB in cell-free systems may be different from those of intact cells.
The present study was designed to analyze pro-apoptotic processes induced by native mouse gzmB under physiological conditions, by using ex vivo-derived, virus-immune mouse gzmB+CTL as a source of gzmB, wt and mutant MEFs as target cells and low effector to target cell ratios (E:T=10:1). The data show that gzmB induces plasma membrane damage by a caspase-3 or -7-dependent pathway, but independently of mitochondrial signaling (Figure 7). The same is true for gzmB-mediated ROS production. However, gzmB induces mitochondrial perturbation by two distinct processes, one involving caspase-3 and/or -7 independently of Bax/Bak to trigger loss of ΔΨm and ROS production, and the other engages Bid and Bak × Bax in the absence of caspase activation to provoke loss of ΔΨm and cytochrome c release (Figure 7). The additional finding that gzmB+CTL abrogates target cell proliferation, most likely by inducing cell death, even upon inhibition of both, caspases and mitochondrial events, suggests additional cytosolic targets that mediate gzmB-induced cell death and emphasizes the pleiotropic pro-apoptotic potential of gzmB.
Genetic and functional analyses indicate that gzmB is the only protease contributing to the gzmB+CTL-mediated pro-apoptotic and cytolytic activities observed. Although all ex vivo-derived virus-immune CTLs expressed transcripts for gzmK the putative protein did not act by itself, as gzmA × B−/−CTL, which expressed perf and gzmK transcripts, but neither gzmA, gzmB or any of the other gzms, including C, D, E, F and M, were able to induce any of the pro-apoptotic processes analyzed or to cause cell death under similar conditions (Supplementary Figure S1d; 3a-c; and Pardo and colleagues6, 27 and Revell et al.28). This contrasts with a recent report which suggests that gzmA × B−/−CTLs are able to induce, at least to some limited extent, cell death and pro-apoptotic processes, such as PS translocation, by mechanisms distinct from classical apoptosis.29 This discrepancy may be due to the fact that the latter studies employed in vitro-propagated rather than ex vivo CTL, and that in vitro-cultivated CTLs express different patterns of gzms, including gzmC (Revell et al.28 and own unpublished results), distinct from those seen in ex vivo-derived LCMV-immune gzmB+CTL. The data obtained with ex vivo-derived LCMV-immune perf−/− and gzmA × B−/−CTL also exclude a contribution of the FasL/Fas system to gzmB+CTL-mediated pro-apoptotic processes, including cell death, of MEFs observed.
The notion that caspases, in particular caspase-3, are critical for gzmB-induced plasma membrane disturbance6, 8 is substantiated by our finding showing that gzmB+CTL did not induce PS exposure in caspases-3/-7-deficient MEFs. In addition, we show for the first time that caspase-7 can replace caspase-3 in this gzmB-mediated process and that both enzymes synergize in the pro-apoptotic program. The fact that gzmB induced similar levels of PS exposure in MEF.wt, MEF.Bid−/−, MEF.Bak × Bax−/− and MEF.Casp 9−/− cells, also suggests that activation of caspase-7, like caspase-3,13 is an early event in target cell apoptosis and independent of mitochondrial events, including cytochrome c release and subsequent caspase-9 activation. In light of a recent report showing that caspase-7 is more sensitive to proteolysis by gzmB compared to caspase-3,13 we postulate an important role for caspase-7 in the early phase of CTL-mediated membrane disturbance via gzmB. Although the putative caspase-7 substrate(s), critical for this process, has not yet been identified it is possible that caspase-7, like caspase-3, contributes to plasma membrane blebbing by cleaving the actin remodeling protein gelsolin.30, 31 Alternatively, caspase-7 or other caspases may synergize with gzmB in targeting and perturbing the cytoskeleton by cleaving α-tubulin, the tubulin folding cofactor and/or other relevant proteins, such as filamin and ROCKII.14, 15, 32 However, the data do not exclude the possibility that gzmB+CTL-induced and caspases-3/-7-facilitated PS exposure is modulated by additional processes, including mitochondrial events, under different conditions. Different CTL population may express or deliver different amounts of gzmB causing target cells to enter distinct pathways of apoptosis.
The observation that gzmB+CTL induced ROS production in MEF.wt, MEF.Bid−/− and MEF.Bak × Bax−/−cells, but not in MEFs deficient in caspase-3, -7 or both, is novel. It suggests that a concerted action of the two caspases is required in ROS production and independent of Bax/Bak, but not necessarily caspase-mediated mitochondrial membrane perforation. This extends previous findings which showed that caspase-3 induces ROS production by targeting the p75 subunit of respiratory chain complexes I and II in previously permeabilized mitochondria.9 However, our data are at variance with a recent report showing that purified rat gzmB triggered ROS production from isolated mouse mitochondria, even in the absence of the cytosolic S100 fraction.20 Although unclear at present, this discrepancy may be due to the fact that gzmB and mitochondria were derived from different species. The combined data, however, indicate that mouse gzmB, when delivered via CTL is unable to directly target mitochondria and reveal caspase-3 and -7 as the main executors during gzmB+CTL-induced ROS production.
Our data do not discriminate whether gzmB+CTL-induced ROS only derives from mitochondria, in particular by interference of caspase-3 with the electron transport chain, as suggested before9 or from other sources, such as peroxisomes, the cytosolic NADPH oxidases or cytochrome P-450 enzymes in the endoplasmic reticulum. Future studies will have to identify the exact intracellular source of ROS during gzmB-dependent target cell killing.
gzmB+CTL similarly induced ΔΨm loss in both MEF.Bid−/− and MEF.Bak × Bax−/−, and in MEF.Casp 3 × 7−/− cells, indicating that gzmB triggers two independent pathways resulting in mitochondrial depolarization. These data corroborate, at least partially, previous studies7, 8, 17, 21 and suggest that gzmB elicits ΔΨm loss either via Bid cleavage and subsequent activation of Bak/Bax or by engaging caspase-3 and -7.
The pro-apoptotic events, which accompany the loss of ΔΨm by these two pathways, are however distinct: whereas the Bid/Bad/Bak-dependent pathway involves cytochrome c release, the caspase-3/-7-dependent one is accompanied by ROS production. Interestingly, both pathways appear to be redundant for gzmB+CTL-induced apoptosis, since both have to be blocked to rescue cells from ΔΨm loss. The additional finding that gzmB+CTL did not induce ΔΨm loss and ROS generation in MEF.Bid−/− or MEF.Bak × Bax−/− cells, whose caspases were inhibited by Ac-ZVAD-fmk or Ac-DEVD-fmk, excludes the possibility that gzmB modulates ΔΨm by other, yet unidentified cytosolic and/or mitochondrial proteins as previously suggested by using recombinant mouse gzmB and MEF cells.7 Although this discrepancy has not been resolved, two reasons may be responsible for it; the use of purified gzmB versus ex vivo CTLs and/or the effect of additional factors in the LAK extracts used, as the perf source to deliver gzmB.7
gzmB+CTL-induced cytochrome c release was absent in Bid- or Bak × Bax-deficient MEFs, but proceeded normally in cells lacking caspase-9 or caspase-3, -7 or both. This finding supports previous studies showing that gzmB induces mitochondrial outer membrane permeabilization, via direct cleavage of Bid instead of activating caspase-3, leading to Bak/Bax activation and subsequent release of pro-apoptotic proteins such as cytochrome c from the mitochondrial intermembrane space.8, 12 An alternative pathway has been proposed by which gzmB cleaves the survival factor Mcl-1 to release its BH3-only partner Bim33 with subsequent activation of Bak/Bax. The strict dependence of cytochrome c on Bid in our study excludes, however, a role for Bim as Bak/Bax activator in this gzmB+CTL-mediated process.
The relationship between gzmB-mediated activation of caspases and mitochondrial events, in particular the differential interdependence of Bid and caspase-3 in these processes, has been a matter of controversy.17, 21 Our results obtained with a physiologically relevant gzmB+CTL-target cell system clearly demonstrate that gzmB can do both, readily induce caspase-3/-7 activation and subsequently cause plasma membrane perturbation and ROS production independently of Bid, Bax or Bak (in MEF.Bid−/− and MEF.Bak × Bax−/− cells) as well as use Bid cleavage and Bax/Bak activation to induce cytochrome c release in the absence of caspase-3/-7 activation (in MEF.Casp 3 × 7−/− cells). The latter finding supports data by some7, 8, 17 but contradicts other studies, which showed that cytochrome c release by gzmB was inhibited by the caspase inhibitor Z-VAD-fmk.34, 35
The most novel finding of our study was that gzmB+CTL-abrogated target cell proliferation, most probably by inducing cell death, as monitored by cell survival assays, occurs in the absence of mitochondrial damage (i.e. Bax/Bak activation) and activation of caspases. This result is consistent with and extends our previous study showing that gzmB+CTL-mediated cell death could neither be inhibited by the general caspase inhibitor Ac-ZVAD-fmk nor the antioxidant agent NAC.6 Whether this type of gzmB-induced abrogation of cell proliferation or cell death is characterized by apoptotic or necrotic features, or by both, and whether this pathway of cell arrest or death is of advantage in host defense against pathogens is not yet known and requires further experimentation. However, the fact that one of the early pro-apoptotic feature, i.e. plasma membrane disturbance, including PS exposure, is not observed in target cells that die independently of caspases suggests that they are refractory to elimination by phagocytosis via the PS receptor11 and may hence induce pathological processes in vivo.
The finite genetic space available to the host for its immune defense requires enormous plasticity in its effector function to encompass all the evasion strategies of the multitude of pathogens. The immune system has achieved this in its recognition phase by generating diversity by genetic means of recombination and somatic mutation. Effector mechanisms, such as cytotoxicity leading to cell death via apoptosis, on the other hand have greater constraints in expressing plasticity. One way in possibly achieving diversity of effector function is by generating multiple distinct death pathways employing a limited number of effector molecules.
The data presented here provide evidence that mouse gzmB, one of the important effector molecules of CTL and NK cells, can function via a multitude of pathways all leading to cell death. This plasticity is most likely the result of evolutionary pressures from pathogens trying to evade immune elimination, including cellular cytotoxicity. One example being poxvirus-encoded serine protease inhibitors that can severely curtail cytolytic effector functions, most probably by inhibiting Fas-mediated and caspase-facilitated PS exposure, resulting in uncontrolled viral spread.36 This diversity in effector function of cytolytic pathways will also be to the host's benefit in tumor elimination.
Finally, our data provide evidence that conclusions drawn from experimental results employing more reductionist approaches (i.e. using recombinant enzymes in artificial in vitro settings) may be erroneous in biological context.
Materials and Methods
Mouse strains
Inbred B6, and mouse strains deficient for perf (perf−/−), gzmA (gzmA−/−) and gzmA × B (gzmA × B−/−), bred on the B6 background were maintained at the Max-Planck-Institut für Immunbiologie, Freiburg and analyzed for their genotypes as described.6 Male mice of 8–10 weeks of age were used in all experiments and were performed in accordance with the local animal care commission.
Generation of ex vivo CD8+ cells
Mice were infected with 105 p.f.u. LCMV-WE i.p. according to established protocols.6 On day 8 postinfection, CD8+ cells were positively selected from spleen using α-CD8-MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) with an autoMACS (Miltenyi Biotec) and resuspended in MEM/5% FCS prior to use in cytotoxic assays. Purity of selected CD8+ cells was assessed by FACS staining and found to be between 95 and 98%.
Cell lines, cell culture and reagents
SV40-transformed MEFs were cultured in MEM supplemented with 10% FCS and 2-mercaptoethanol (10−5 M) at 37°C, 7% CO2. Bid−/− and Bax−/− × Bak−/− MEFs were generated and generously provided by the SJ Korsmeyer laboratory and compared to an MEF.wt cell line, generated by the same group. Casp 9−/−, Casp 3−/−, Casp 7−/− and Casp 3 × 7−/− MEFs were generated by the group of Richard A Flavell22 and compared to an MEF.wt cell line generated by the same group. The genotype of the various MEF cells was periodically tested by genomic PCR and western blot analysis. In some cases, the general caspase inhibitor Ac-ZVAD-fmk or the caspase-3/-7 inhibitor Ac-DEVD-fmk (Bachem; 100 μM both) were added to cell cultures as described.6 The mouse cell lines 1.3E6 (CTL) and EL4.F15 (EL4) were cultured as described.37
RT-PCR
Total RNA was extracted from up to 5 × 106 cells, using the QIAshredder spin columns, the RNeasy Mini Kit and the RNase-free DNase Kit (all from Qiagen, Hilden, Germany) according to the manufacturer's instructions, and specific transcripts were amplified. The sense/antisense primers for gzmA and Hprt1 and gzmC, gzmD, gzmE, gzmF and gzmG are described in Martin et al.37 and Revell et al.,28 respectively. Sense/antisense primers for gzmB, gzmK and gzmM were 5′TGCTGACCTTGTCTCTGGCC3′/5′TAGTCTGGGTGGGGAATGCA3′, 5′CATTCCAGGCCATTTATGGC3′/5′GGCAAGCTTGCTTTTTGATCC3′ and 5′ATGGAGGTCTGCTGGTCC3′/5′TCCAGGAGCTGTAGGGGG3′, respectively.
Flow cytometry
Cell populations were analyzed for cell surface marker expression, pentamer staining and/or intracellular expression of gzmA and gzmB by FACS as described.37 In all cases, cells were incubated with anti(α)-FcR-antibody (clone 2.4G2) prior to the first staining step. Detection of LCMV-immune CTL was conducted by staining MACS-selected CD8+ T cells with gp33-labeled pentamers (H-2Db pent-PE). Rabbit immune serum (IS) specific for mouse gzmA (α-mgzmA) has been described.37 Rabbit α-mouse gzmB (α-mgzmB) IS was generated by repeated immunization of rabbits with pro-rec.gzmB as described for α-mgzmA IS.
Lamp-1 mobilization assay
Lamp-1 (CD107a) expression in the cell membrane of ex vivo CTLs was analyzed as described.38 Briefly, MEF cells were pretreated with the LCMV-immunodominant peptide gp33 for 2 h prior to incubation with ex vivo-derived LCMV-immune CTL at 2:1 E:T cell ratio (triplicates, 4 × 104 targets and 8 × 104 CTLs/well). Subsequently, the mixed cell population was treated with 1 μl (final dilution 1:200) of α-Lamp-1-FITC antibody (BD Pharmingen) in the presence of monensin for 6 h at 37°C, 7% CO2. Non-attached cells were collected, labeled with α-CD8-APC antibody and analyzed by FACS.
Analysis of pro-apoptotic processes
Cell death induced by ex vivo CTL in MEF cells was analyzed as described.6 MEF cells were pretreated with the LCMV-immunodominant peptide gp33 for 2 h prior to incubation with ex vivo-derived LCMV-immune CTL at 10:1 E:T cell ratio for 4 h at 37°C, 7% CO2.6 Subsequently, different apoptotic parameters were tested in the target population (CD8−) by FACS with a FACScan (BD Pharmingen) and CellQuest® software as follows:
Cell membrane and mitochondrial membrane perturbations: PS exposure and PI uptake were analyzed by FACS as described6 using the annexin-V-FITC kit from BD Pharmingen. The mitochondrial membrane potential was measured with the fluorescent probe 3,3′-dihexyloxacarbocyanine iodide (DiOC6(3); Molecular Probes) and ROS generation with 2-hydroxyethidium (2-HE; Molecular Probes) as described.6
Caspase-3 activation: Caspase-3 activation was analyzed by FACS as described.6 Cells were fixed with 4% paraformaldehyde (PFA) and incubated with an FITC-labeled monoclonal antibody against the active form of caspase-3 (clone C92605; BD Pharmingen) diluted in 0.1% saponin in PBS. After two washes with 0.1% saponin in PBS, cells were resuspended in 1% PFA/PBS and analyzed by FACS.
Cytochrome c release: Cytochrome c release was quantified by FACS analysis as recently described.39 Briefly, MEFs (1 × 106) were mildly permeabilized with 25 μg/ml digitonin plus 100 mM KCl on ice for 5 min. This leads to loss of cytosolic cytochrome c. Cells were washed once with cold PBS, fixed in 4% PFA, permeabilized with 0.05% saponin and 3% BSA and then incubated with the α-cytochrome c mAb 6H2.B4 (BD Pharmingen) or with mouse IgG isotype as control (Jackson) followed by α-mouse-Alexa 544 secondary antibody (Invitrogen). Cells were resuspended in 100 μl PFA in PBS and analyzed by FACS.
Conformational change of Bax and Bak: Bak and Bax conformational change was analyzed in target cell populations as described.40 Briefly, MEFs were fixed in 4% PFA, permeabilized with 0.1% saponin in PBS/5% FCS and incubated with polyclonal rabbit α-Bak (NT; Upstate Biotechnology), polyclonal rabbit α-Bax (NT; Upstate Biotechnology) or purified rabbit IgG (control). After washing (2 × ) with 0.1% saponin in PBS, cells were incubated with α-rabbit-Alexa 488 antibody (Invitrogen) in 0.1% saponin/PBS/5% FCS, washed twice in 0.1% saponin/PBS, resuspended in 1% PFA/PBS and analyzed by FACS.
Analysis of Bid cleavage
MEF.wt cells were pretreated with the LCMV-immunodominant peptide gp33 for 2 h prior to incubation with ex vivo-derived LCMV-immune CTL at 10:1 E:T cell ratio for 1 h at 37°C, 7% CO2.6 Subsequently, cells were washed twice in cold PBS and lysed in a buffer containing 1% Triton X-100, a protease inhibitor cocktail (Roche) and 100 μM DCI at 4°C during 1 h. Soluble protein fractions were recovered by centrifugation, separated by SDS polyacrylamide gel electrophoresis (15%) and transferred onto PVDF membranes. Bid was analyzed by using a rat anti-Bid Ab (a generous gift of David Huang) that recognizes both the non-cleaved (22 kDa) and the truncated protein (tBid; 16 kDa).
Survival assays
Survival of target cells following their incubation with CTL was analyzed as described.27 This assay gives similar results to clonogenic survival assay in agar plates (AM, unpublished observations). Accordingly, MEF cells were pretreated with the LCMV-immunodominant peptide gp33 (2 h) prior to incubation with ex vivo-derived LCMV-immune CTLs at 10:1 E:T cell ratio for 4 h. Wells were washed once with MEM plus 2% FCS to remove non-adherent cells and attached cells were resuspended in MEM plus 2% FCS. No viable cells were detected among the non-adherent cells. Target cell survival was quantified by 3H-thymidine incorporation during the next 24 h as described.27
Abbreviations
- B6:
-
C57BL/6
- Casp:
-
caspase
- CTL:
-
cytotoxic T lymphocyte
- DiOC6(3):
-
3,3′-dihexyloxacarbocyanine iodide
- gzm:
-
granzyme
- 2-HE:
-
dihydroethidium
- LCMV:
-
lymphocytic choriomeningitis virus
- MEF:
-
mouse embryonic fibroblast
- ΔΨm:
-
mitochondrial transmembrane potential
- NK:
-
natural killer
- perf:
-
perforin
- PI:
-
propidium iodide
- PS:
-
phosphatidylserine
- ROS:
-
reactive oxygen species
References
Russell JH, Ley TJ . Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323–370.
Simon MM, Kramer MD . Granzyme A. Methods Enzymol 1994; 244: 68–79.
Tschopp J . Granzyme B. Methods Enzymol 1994; 244: 80–87.
Lieberman J . The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003; 3: 361–370.
Trapani JA, Sutton VR . Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003; 15: 533–543.
Pardo J, Bosque A, Brehm R, Wallich R, Naval J, Mullbacher A et al. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol 2004; 167: 457–468.
Thomas DA, Scorrano L, Putcha GV, Korsmeyer SJ, Ley TJ . Granzyme B can cause mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK. Proc Natl Acad Sci USA 2001; 98: 14985–14990.
Bleackley RC . A molecular view of cytotoxic T lymphocyte induced killing. Biochem Cell Biol 2005; 83: 747–751.
Ricci JE, Munoz-Pinedo C, Fitzgerald P, Bailly-Maitre B, Perkins GA, Yadava N et al. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 2004; 117: 773–786.
Simizu S, Takada M, Umezawa K, Imoto M . Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem 1998; 273: 26900–26907.
Savill J, Fadok V . Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784–788.
Waterhouse NJ, Sedelies KA, Sutton VR, Pinkoski MJ, Thia KY, Johnstone R et al. Functional dissociation of DeltaPsim and cytochrome c release defines the contribution of mitochondria upstream of caspase activation during granzyme B-induced apoptosis. Cell Death Differ 2006; 13: 607–618.
Adrain C, Murphy BM, Martin SJ . Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J Biol Chem 2005; 280: 4663–4673.
Adrain C, Duriez PJ, Brumatti G, Delivani P, Martin SJ . The cytotoxic lymphocyte protease, granzyme B, targets the cytoskeleton and perturbs microtubule polymerization dynamics. J Biol Chem 2006; 281: 8118–8125.
Goping IS, Sawchuk T, Underhill DA, Bleackley RC . Identification of {alpha}-tubulin as a granzyme B substrate during CTL-mediated apoptosis. J Cell Sci 2006; 119: 858–865.
Bredemeyer AJ, Townsend RR, Ley TJ . Use of protease proteomics to discover granzyme B substrates. Immunol Res 2005; 32: 143–153.
Waterhouse NJ, Sedelies KA, Trapani JA . Role of Bid-induced mitochondrial outer membrane permeabilization in granzyme B-induced apoptosis. Immunol Cell Biol 2006; 84: 72–78.
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675–1687.
Green DR, Kroemer G . The pathophysiology of mitochondrial cell death. Science 2004; 305: 626–629.
Martinvalet D, Zhu P, Lieberman J . Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity 2005; 22: 355–370.
Metkar SS, Wang B, Ebbs ML, Kim JH, Lee YJ, Raja SM et al. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol 2003; 160: 875–885.
Lakhani SA, Masud A, Kuida K, Porter Jr GA, Booth CJ, Mehal WZ et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006; 311: 847–851.
Waterhouse NJ, Sedelies KA, Browne KA, Wowk ME, Newbold A, Sutton VR et al. A central role for Bid in granzyme B-induced apoptosis. J Biol Chem 2005; 280: 4476–4482.
Casciola-Rosen L, Garcia-Calvo M, Bull HG, Becker JW, Hines T, Thornberry NA et al. Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem 2007; 282: 4545–4552.
Cullen SP, Adrain C, Luthi AU, Duriez PJ, Martin SJ . Human and murine granzyme B exhibit divergent substrate preferences. J Cell Biol 2007; 176: 435–444.
Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, Whisstock JC et al. The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol 2006; 175: 619–630.
Pardo J, Balkow S, Anel A, Simon MM . Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. Eur J Immunol 2002; 32: 2881–2887.
Revell PA, Grossman WJ, Thomas DA, Cao X, Behl R, Ratner JA et al. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. J Immunol 2005; 174: 2124–2131.
Waterhouse NJ, Sutton VR, Sedelies KA, Ciccone A, Jenkins M, Turner SJ et al. Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J Cell Biol 2006; 173: 133–144.
Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278: 294–298.
Slee EA, Adrain C, Martin SJ . Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320–7326.
Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breard J . Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 2005; 201: 465–471.
Han J, Goldstein LA, Gastman BR, Rabinovitz A, Rabinowich H . Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem 2005; 280: 16383–16392.
MacDonald G, Shi L, Vande Velde C, Lieberman J, Greenberg AH . Mitochondria-dependent and -independent regulation of granzyme B-induced apoptosis. J Exp Med 1999; 189: 131–144.
Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000; 192: 1403–1414.
Müllbacher A, Waring P, Hia RT, Tran T, Chin S, Stehle T et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA 1999; 96: 13950–13955.
Martin P, Wallich R, Pardo J, Mullbacher A, Munder M, Modolell M et al. Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes? Blood 2005; 106: 2871–2878.
Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 1377–1382.
Waterhouse NJ, Trapani JA . A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ 2003; 10: 853–855.
Pardo J, Urban C, Galvez EM, Ekert PG, Muller U, Kwon-Chung J et al. The mitochondrial protein Bak is pivotal for gliotoxin-induced apoptosis and a critical host factor of Aspergillus fumigatus virulence in mice. J Cell Biol 2006; 174: 509–519.
Acknowledgements
We thank Anton Grubisic, Aynur Ekiciler and Thomas Stehle for expert technical assistance. We also thank Pierre Golstein for his critical comments and stimulating discussions, Lars Joeckel for reading the manuscript and David Huang for the antiBid antibody. JP was supported by the Alexander von Humboldt foundation and by a research contract from Aragon I+D.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by SJ Martin
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Supplementary information
Rights and permissions
About this article
Cite this article
Pardo, J., Wallich, R., Martin, P. et al. Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death Differ 15, 567–579 (2008). https://doi.org/10.1038/sj.cdd.4402289
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4402289
Keywords
This article is cited by
-
Granzyme serine proteases in inflammation and rheumatic diseases
Nature Reviews Rheumatology (2024)
-
Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells
Cell Death & Disease (2023)
-
Association of GZMB polymorphisms and susceptibility to non-segmental vitiligo in a Korean population
Scientific Reports (2021)
-
Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance
Cell Death & Differentiation (2018)
-
Granzyme K‐deficient mice show no evidence of impaired antiviral immunity
Immunology & Cell Biology (2017)